Crispr'd Cells Show Promise in First US Human Safety Trial

It’s been over three years since US regulators greenlit the nation’s first in-human test of Crispr’s disease-fighting potential, more than three years of waiting to find out if the much-hyped gene-editing technique could be safely used to beat back tough-to-treat cancers. Today, researchers from the University of Pennsylvania and Stanford finally revealed the first published report describing the trial.

Learn about your ad choices: dovetail.prx.org/ad-choices